Clinical Trial Update: Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of a 9-valent HPV recombinant vaccine in Chinese healthy females has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma in Situ
• Cervical Cancer
• Cervical Intraepithelial Neoplasia 1
• Cervical Intraepithelial Neoplasia 2
• Cervical Intraepithelial Neoplasia 3
• Genital Warts
• Hpv Infections
• Vaginal Cancer
• Vaginal Intraepithelial Neoplasia 1
• Vaginal Intraepithelial Neoplasia 2
• Vaginal Intraepithelial Neoplasia 3
• Vulvar Cancer
• Vulvar Intraepithelial Neoplasia 1
• Vulvar Intraepithelial Neoplasia 2
• Vulvar Intraepithelial Neoplasia 3

Snippet

Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Conditions: HPV Infections, Cervical Cancer | Phase 3 | Status: COMPLETED